Gene therapy and High-Tech glasses aim to restore sight in blinding eye disease
NCT ID NCT03326336
Summary
This early-stage study is testing the safety of a new gene therapy called GS030 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive a single injection into the eye and then use special stimulating glasses daily. The main goal is to see if the combined treatment is safe and tolerable, while also checking for any early signs that it might improve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SYNDROMIC RETINITIS PIGMENTOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts
Paris, 75012, France
-
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
London, United Kingdom
-
UPMC Eye Center
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.